Mineralys Therapeutics, Inc.
MLYSHeld by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (lorundrostat): Dec 2025. Short interest: 12.7% of float.
Held by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (lorundrostat): Dec 2025. Short interest: 12.7% of float.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.